Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug 20;5(2):608.
doi: 10.4022/jafib.608. eCollection 2012 Aug-Sep.

Primary Prevention of Atrial Fibrillation where are we in 2012?

Massimo Imazio  1
Affiliations
Review

Primary Prevention of Atrial Fibrillation where are we in 2012?

Massimo Imazio. J Atr Fibrillation. .

Abstract

Drugs to alter or delay myocardial remodelling associated with heart failure, hypertension, or inflammation in the post-operative setting, may prevent the development of atrial fibrillation. Current experimental and clinical evidences support specific treatments for defined patient population (i.e. ACE-inhibitors and ARB for chronic heart failure and hypertension expecially with LV hypertrophy; statins, corticosteroids and possibly colchicine after cardiac surgery).

Keywords: atrial fibrillation; prevention..

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Upstream therapies may affect the underlying disease (i.e. ACEi, ARB, statins), the substrate, the triggers (i.e. inflammation for statins, corticosteroids, and colchicine), and the remodelling process (all agents) preventing atrial fibrillation at different levels and mechanisms.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Miyasaka Yoko, Barnes Marion E, Gersh Bernard J, Cha Stephen S, Bailey Kent R, Abhayaratna Walter P, Seward James B, Tsang Teresa S M. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114 (2):119–25. - PubMed
    1. Naccarelli Gerald V, Varker Helen, Lin Jay, Schulman Kathy L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am. J. Cardiol. 2009 Dec 01;104 (11):1534–9. - PubMed
    1. Heeringa Jan, van der Kuip Deirdre A M, Hofman Albert, Kors Jan A, van Herpen Gerard, Stricker Bruno H Ch, Stijnen Theo, Lip Gregory Y H, Witteman Jacqueline C M. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 2006 Apr;27 (8):949–53. - PubMed
    1. Wolowacz S E, Samuel M, Brennan V K, Jasso-Mosqueda J-G, Van Gelder I C. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011 Oct;13 (10):1375–85. - PubMed
    1. Wodchis Walter P, Bhatia R Sacha, Leblanc Kori, Meshkat Nazanin, Morra Dante. A review of the cost of atrial fibrillation. Value Health. 2012 Mar 22;15 (2):240–8. - PubMed

LinkOut - more resources